In this free webinar, learn how the adoption of animal-free reagents is crucial for ensuring safe production processes in biomanufacturing. Attendees will learn how recombinant insulin is a key ingredient in various biomanufacturing processes. The featured speakers will share how controlled manufacturing processes for the production of recombinant reagents such as trypsin is crucial. The speakers will also discuss how recombinant insulin has the potential to drive cost savings within biomanufacturing, reducing overall upstream costs.
TORONTO, Feb. 25, 2025 /PRNewswire-PRWeb/ -- The use of animal-free reagents in the upstream manufacturing of biologic drugs is a common standard in biomanufacturing, essential for enhancing consistency and safety.
Insulin has emerged as a key component in cell culture for biomanufacturing, improving a wide array of processes such as monoclonal antibody (mAb) production in CHO cells, virus production in various cell types, stem cell culture performance and production of viral vectors for gene therapy.
Another crucial element in cell-based vaccine production is trypsin, which is essential for virus expansion and activation of specific virus particles, notably in the case of influenza. However, the use of animal-derived trypsin carries the inherent risk of introducing adventitious contaminants, potentially leading to cell culture infection with serious consequences for both patients and production continuity.
The introduction of the new enzyme TrypsiNNex® effectively addresses these safety and consistency concerns. As a high-purity, recombinantly produced, animal-free trypsin, the enzyme ensures a more robust production process, effectively reducing the risk of contamination.
Through a controlled production process, the enzyme maintains an inactive form until stabilization, which results in a high and consistent proportion of β-trypsin and makes it an ideal choice for virus-vaccine production, resulting in cost savings and improved efficiency.
In this webinar, the expert speakers will illustrate how both recombinant insulin and TrypsiNNex® significantly enhance the safety and efficiency of upstream biomanufacturing processes, thereby enhancing the overall efficiency of therapeutic biologics production. Furthermore, they will delve into how the implementation of reagents such as insulin plays a significant role in reducing overall upstream costs by increasing process efficiency.
Register for this webinar today to explore how innovative animal-free reagents are transforming upstream biomanufacturing.
Join experts from Novo Nordisk Pharmatech A/S, Sara Bursomanno, PhD, Senior Global Product Manager; and Marie-Louise Lunn, PhD, Senior Global Product Manager, for the live webinar on Wednesday, March 19, 2025, at 9:30am EDT (2:30pm CET/EU-Central).
For more information, or to register for this event, visit Enhancing Efficiency and Safety in Upstream Biomanufacturing.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article